Strategic partnerships RiconPharma has established or pursued multiple development and manufacturing partnerships across the US, Canada, Europe, and India, indicating a readiness and openness to alliance-based growth. This creates sales opportunities for contract development and manufacturing services, technology transfer, and co-development deals in transdermal patches and other dosage forms.

Transdermal focus The company is actively seeking partners for transdermal patch development and commercialization, presenting a clear entry point for BD teams to offer patch formulation expertise, clinical support, regulatory pathways, and large-scale manufacturing capabilities.

Comprehensive capabilities With 65 years of combined experience in pharmaceutical development, QA/QC, regulatory affairs, and a diverse product pipeline (solids, liquids, topicals, patches, injectables), RiconPharma can position as a full-service development and manufacturing partner to accelerate timelines for complex dosage forms.

Global footprint Dual facilities in the US and India enable potential nearshoring/flexibility for cost-effective production, regional regulatory support, and risk mitigation, which is attractive to multinational companies seeking diversified manufacturing networks.

IP and litigation signals Historical collaboration with Ingenus and a patent-related lawsuit with Supernus highlight a dynamic IP landscape, suggesting a need for robust patent clearance, freedom-to-operate assessments, and strategic partnerships to navigate competitive protections while pursuing development opportunities.